Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment.,Clinical & Translational Immunology

当前位置： X-MOL 学术 › Clin. Transl. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment.
Clinical & Translational Immunology ( IF 4.6 ) Pub Date : 2020-08-15 , DOI: 10.1002/cti2.1165
Jonas Rm Van Audenaerde _{1,

2} , Elly Marcq ₁ , Bianca von Scheidt ₂ , Ashleigh S Davey ₂ , Amanda J Oliver ₂ , Jorrit De Waele ₁ , Delphine Quatannens ₁ , Jinthe Van Loenhout ₁ , Patrick Pauwels _{1,

3} , Geert Roeyen ₄ , Filip Lardon ₁ , Clare Y Slaney _{2,

5} , Marc Peeters _{1,

6} , Michael H Kershaw _{2,

5} , Phillip K Darcy _{2,

5} , Evelien Ljm Smits _{1,

7}

Affiliation

With the poorest 5‐year survival of all cancers, improving treatment for pancreatic cancer is one of the biggest challenges in cancer research. We sought to explore the potential of combining both priming and activation of the immune system. To achieve this, we combined a CD40 agonist with interleukin‐15 and tested its potential in pancreatic cancer.

中文翻译：

胰腺癌的新型联合免疫疗法：CD40 激动剂和白细胞介素 15 治疗的有效抗肿瘤作用。

由于所有癌症的 5 年生存率最低，因此改善胰腺癌的治疗是癌症研究的最大挑战之一。我们试图探索结合免疫系统的启动和激活的潜力。为了实现这一目标，我们将 CD40 激动剂与白细胞介素 15 结合，并测试了其在胰腺癌中的潜力。

更新日期：2020-08-16

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文